No abstract is available for this article.
Bibliography
- 1 M. Y. Chiang et al. (1991) J. Biol. Chem. 266, 18162–18171.
- 2 C. F. Bennett and S. T. Crooke (1996) Oligonucleotide-based inhibitors of cytokine expression and function. In Therapeutic Modulation of Cytokines ( B. Henderson, and M. W. Bodmer eds.), CRC Press, Boca Raton, pp. 171–193.
- 3 E. De Clercq, F. Eckstein, and T. C. Merigan (1969) Science 165, 1137–1140.
- 4 W. F. Lima et al. (1992) Biochemistry 31, 12055–12061.
- 5 T. Vickers et al. (1991) Nucleic Acids Res. 19, 3359–3368.
- 6 B. P. Monia et al. (1993) J. Biol. Chem. 268, 14514–14522.
- 7 B. P. Monia et al. (1992) J. Biol. Chem. 267, 19954–19962.
- 8 S. T. Crooke et al. (1996) J. Pharmacol. Exp. Ther. 277(2), 923–937.
- 9 R. W. Joos and W. H. Hall (1969) J. Pharmacol. Exp. Ther. 166, 113–118.
- 10 S. K. Srinivasan, H. K. Tewary, and P. L. Iversen (1995) Antisense Res. Dev. 5(2), 131–139.
- 11 S. T. Crooke et al. (1995) Biochem. J. 312(2), 599–608.
- 12 W. Y. Gao et al. (1992) Mol. Pharmacol. 41, 223–229.
- 13 C. Majumdar et al. (1989) Biochemistry 28, 1340–1346.
- 14 Y. Cheng, W. Gao, and F. Han (1991) Nucleosides Nucleotides 10, 155–166.
- 15 C. A. Stein et al. (1991) Acquired Immune Defic. Syndr. 4, 686–693.
- 16 C. A. Stein and Y. C. Cheng (1993) Science, 261, 1004–1012.
- 17 D. Hodges and S. T. Crooke (1995) Mol. Pharmacol., 48, 905–918.
- 18 S. Agrawal, J. Temsamani, and J. Y. Tang (1991) Proc. Natl. Acad. Sci. USA 88, 7595–7599.
- 19 P. Iversen (1991) Anticancer Drug Des. 6(6), 531–8.
- 20 P. A. Cossum et al. (1994) J. Pharmacol. Exp. Ther. 269, 89–94.
- 21 S. T. Crooke et al. (1994) Clin. Pharm. Ther. 56, 641–646.
- 22 P. A. Cossum et al. (1993) J. Pharmacol. Exp. Ther. 267, 1181–1190.
- 23 J. Rappaport et al. (1995) Kidney Int. 47, 1462–1469.
- 24 R. F. Azad et al. (1993) Antimicrob. Agents Chemother. 37(9), 1945–1954.
- 25 R. W. Wagner et al. (1993) Science 260, 1510–1513.
- 26 J. R. Wyatt et al. (1994) Proc. Natl. Acad. Sci. USA 91, 1356–1360.
- 27 C. M. Barton and N. R. Lemoine (1995) Br. J. Cancer 71, 429–437.
- 28 T. L. Burgess et al. (1995) Proc. Natl. Acad Sci USA 92, 4051–4055.
- 29 M. Hertl, L. M. Neckers, and S. I. Katz (1995) J. Invest. Dermatol. 104, 813–818.
- 30 S. T. Crooke (1995) Therapeutic Applications of Oligonucleotides, R. G. Landes, Austin, TX.
- 31 N. M. Dean and R. McKay (1994) Proc. Natl. Acad. Sci. USA 91, 11762–11766.
- 32 N. M. Dean et al. (1996) Cancer Res. 56(15), 3499–3507.
- 33 B. P. Monia et al. (1995) Nature Med. 2(6), 668–675.
- 34
B. Monia et al.
(1996)
J. Biol. Chem.
24(14),
14533–14540.
10.1074/jbc.271.24.14533 Google Scholar
- 35 S. P. Henry et al. (1997) Toxicology 116(1–3), p. 77–88.
- 36 S. P. Henry et al. Antisense Nucleic Acid Drug Dev., In Press.
- 37 S. Henry et al. J. Pharmacol. Exp. Ther., In Press.
- 38 K. G. Cornish et al. (1993) Pharmacol. Commun., 3, 239–247.
- 39 W. M. Galbraith et al. (1994) Antisense Res. Dev. 4(3), 201–206.
- 40 S. Henry, W. Novotny, and J. Leeds. Submitted.
- 41 S. L. Hutcherson et al. (1995) Abstracts of the SFO, CA, 35th ICAAC, p. 204.
- 42 J. M. Glover et al. (1996) Pharmacol. Exp. Ther., In Press.
- 43 D. S. Boyer et al. (1997) In AAO Annual Meeting, San Francisco.
- 44 B. R. Yacyshyn et al. N. Engl. J. Med., Submitted.
- 45 Y. S. Sanghvi, and P. D. Cook (1994) Symposium Series No. 580 American Chemical Society, Washington, DC, p. 232.
Suggestions for Further Reading
- S. T. Crooke and B. Lebleu (1993) Antisense Research and Applications, CRC Press, Boca Raton.
- S. T. Crooke (1992) Ann. Rev. Pharmacol. Toxicol. 32, 329–376.
- S. T. Crooke (1993) FASEB J. 7, 533–539.
- S. M. Freier (1993) Hybridization considerations affecting antisense drugs, In Antisense Research and Applications ( S. T. Crooke and B. Lebleu, eds.), CRC Press, Boca Raton, pp. 67–82.
- S. T. Crooke (1995) Therapeutic Applications of Oligonucleotides, R. G. Landes, Austin.
